Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors
复制标题
DOI：
10.3851/imp2551
复制
发表时间：
2014-01-01
影响因子：
--
通讯作者：
Margolis, David M.
中科院分区：
文献类型：
--
作者：
McManamy, Mary E. Manson;Hakre, Shweta;Margolis, David M.
HIV-1在潜伏感染的CD4+T细胞中的持久性阻止了HIV感染治疗患者的根除。潜伏期的特征是整合的HIV-1转录的可逆沉默。已经描述了几种导致潜伏期的分子机制，包括在HIV-1启动子上建立和维持抑制染色质。组蛋白去乙酰化是一个里程碑式的修饰，与HIV-1启动子的转录抑制和组蛋白脱乙酰酶(HDAC)的抑制重新激活潜伏的HIV-1有关。在这里，我们综述了不同的HDAC抑制剂已被研究的HIV-1潜伏期及其在重新激活潜伏期HIV-1的治疗潜力。
Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.